Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002286
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients
Sponsor:
Glaxo Wellcome
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Retrovir Capsules in the Treatment of Psoriasis in HIV Antibody Positive Patients A Pilot Study
Status:
COMPLETED
Status Verified Date:
1989-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the feasibility of Retrovir AZT in the treatment of psoriasis in HIV antibody positive patients Retrovir has been shown to be effective in the treatment of AIDS In addition the administration of AZT appears to have induced a remission of psoriasis in one case study In light of AZTs antiviral activity and potential effectiveness as an agent for the treatment of psoriasis this would be the most likely treatment for HIV positive psoriatic patients whose disease progresses quickly
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 16 | None | None | None |